| Acceptance rate | 46% |
|---|---|
| Time to first decision | 20 days* |
| Time to decision with review | 50 days* |
*Approximate number of days
**The days mentioned above are averages and do not indicate exact durations. The process may vary for each article.
ACTA Pharmaceutica Sciencia
2023 , Vol 61 , Num 4
A cross-sectional study on the knowledge of pharmacists about Alzheimer"s Disease: enhancing services for patients and caregivers
1 Clinical Pharmacy Department, Faculty of Pharmacy, Bezmialem Vakif University, Istanbul, TürkiyeDOI : 10.23893/1307-2080.APS6123 Alzheimer"s disease (AD) is a progressive neurodegenerative disorder impacting cognitive function and daily activities. Pharmacists" accessibility enables them to contribute to rational drug use, monitor interactions, and educate patients and caregivers, improving health outcomes. This study investigates pharmacists" knowledge of AD. A descriptive study in Türkiye utilized a web-based questionnaire with demographic questions and the Alzheimer"s Disease Knowledge Scale (ADKS). 185 participants (72.43% female, mean age 36.9±11.9) exhibited significant knowledge of Alzheimer"s disease (mean ADKS score: 7.48±1.18). Scores varied across factors like gender, age groups, professional experience, and geographical region. Statistically significant correlations were found between these factors and specific domains of AD knowledge. AD necessitates specialized care, and pharmacists" services improve health outcomes for patients and families. Cognitive pharmacy services for complex treatment regimens benefit AD patients and their relatives. A multidisciplinary approach is crucial in effectively addressing the impact of AD and providing optimal treatment. Keywords : Alzheimer"s disease, pharmacists, knowledge, ADKS, dementia